Vytrus Biotech projects that by 2027, 60% of its revenue will be derived from its current plant stem cell business, with the remaining 40% coming from...
Vytrus Biotech closed 2022 with a capitalization of more than €24 million, an increase of 98% since its debut on BME Growth, the SME stock market,...